GenKyoTex SA represents values of innovation, commitment, and scientific excellence. With a strong corporate philosophy focused on pioneering novel therapies, GenKyoTex SA aims to revolutionize the field of fibrosis and inflammatory diseases. By leveraging their expertise in selective modulators of NOX enzymes, the company is dedicated to developing breakthrough treatments for conditions like primary biliary cholangitis and diabetic nephropathy. GenKyoTex SA's commitment to advancing patient care is exemplified through their robust pipeline of innovative drug candidates, combining cutting-edge science and clinical expertise. Through their unwavering dedication to improving patients' lives, GenKyoTex SA has emerged as a key player in the biopharmaceutical industry.

GenKyoTex SA is primarily present in multiple countries and regions worldwide. The company has a global presence, with a strong focus on Europe and the United States. Additionally, GenKyoTex SA actively operates in Asia, particularly in countries like Japan and China. With its diverse international operations, GenKyoTex SA continues to expand its market reach and establish strategic partnerships across different regions.

GenKyoTex SA has achieved several significant milestones in its journey. Notably, the company successfully developed its lead product candidate, setanaxib, which holds immense potential for treating numerous fibrotic diseases. Additionally, GenKyoTex SA has demonstrated positive clinical trial results, showcasing the efficacy and safety of setanaxib. The company has also fostered strategic collaborations with renowned pharmaceutical partners, further validating its innovative research and development approach. With its consistent dedication to advancing therapeutic solutions for fibrosis and inflammatory diseases, GenKyoTex SA continues to make noteworthy strides in revolutionizing patient care.

GenKyoTex SA is a renowned biopharmaceutical company with an intriguing history and background. Established in [year], GenKyoTex has made significant strides in the field of [specific area of focus]. The company's foundation is built upon groundbreaking research and a team of experienced professionals dedicated to improving [relevant field]. GenKyoTex has collaborated with esteemed organizations to develop innovative therapies and enhance the quality of life for patients suffering from [specific condition]. With a commitment to scientific excellence and a strong emphasis on [key values], GenKyoTex has emerged as a leader in the biopharmaceutical industry, demonstrating promising potential for future growth and advancements in the field.

The main competitors of GenKyoTex SA in the market are other pharmaceutical companies operating in the same therapeutic area or focusing on similar drug development. Some notable competitors include ABC Pharmaceuticals, XYZ Biotech, and PQR Therapeutics. These companies directly compete with GenKyoTex SA by developing and commercializing similar products or treatments for the benefit of patients. By understanding the competitive landscape, investors and stakeholders can gain insights into GenKyoTex SA's position in the market and evaluate its potential for growth and success.

GenKyoTex SA is primarily active in the biotechnology and pharmaceutical industries.

The business model of GenKyoTex SA focuses on developing and commercializing innovative therapeutics for the treatment of various diseases. The company specializes in targeting and modulating enzymes involved in different pathologies, aiming to provide novel therapeutic solutions. GenKyoTex SA utilizes its expertise in oxidative stress modulation to develop small molecules that have the potential to address a wide range of diseases, including kidney and liver disorders, fibrosis, and metabolic disorders. By leveraging its scientific knowledge and strategic collaborations, GenKyoTex SA aims to deliver breakthrough therapies that can significantly impact patients' lives.

De GenKyoTex K/W is 0.

De GenKyoTex KUV is -0,00.

De AlleAktien Kwaliteitsscore voor GenKyoTex is 1/10.

De verwachte GenKyoTex omzet is -9.186,90 Ltd. .

De winst kan momenteel niet berekend worden voor GenKyoTex.

GenKyoTex SA is a biopharmaceutical company that focuses on the development of innovative therapies for the treatment of diseases of the nervous system, inflammation, and cancer. The company operates in two main areas: clinical development and preclinical research and development. The clinical development focuses on the exploration of drugs that target specific cells in the body that are involved in the development of diseases. This area includes Phase II and Phase III studies leading to drug approval by the relevant authorities. GenKyoTex works closely with clinical research centers and patient organizations to ensure that the drugs meet the needs of patients. The preclinical area of GenKyoTex includes research and development in the fields of molecular biology, biology, and chemistry, which lead to the identification of new target molecules and drugs. Here, GenKyoTex develops new technologies that help increase the effectiveness and safety of drugs. Preclinical studies are also an important step in the development of new drugs. GenKyoTex's portfolio includes various products that are still in various stages of development. One of the main candidates is GKT831, a potential drug for kidney diseases. This drug is intended to prevent the formation of scar tissue in the kidneys and thus improve kidney function. The positive effect of the drug has been proven in both preclinical and clinical studies. At the same time, active research on GKT831 for the treatment of dental genetic diseases is ongoing. Another important candidate in GenKyoTex's portfolio is GKT771, for the treatment of fibrotic diseases. Fibrosis encompasses a group of diseases in which chronic inflammation leads to excessive formation of connective tissue, which can impair vital organs. The drug has the potential to reduce the formation of connective tissue and thus slow the progression of severe symptoms. Through collaboration with renowned research and development organizations and universities, GenKyoTex has access to the most advanced research methods and technologies, enabling it to develop innovative drugs and therapies for patients. Overall, GenKyoTex aims to improve the quality of life for patients and contribute to the cure of serious illnesses. The company pursues a variety of research and development projects, from the identification of target molecules to the clinical development of drugs. It works closely with the medical community and patient organizations to ensure that its products meet the needs of patients.

GenKyoTex keert een dividend van 0 uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor GenKyoTex of het bedrijf keert geen dividend uit.

De ISIN van GenKyoTex is FR0013399474.

Het WKN van GenKyoTex is A2PE0M.

De ticker van GenKyoTex is GKTX.PA.

Binnen de laatste 12 maanden betaalde GenKyoTex een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal GenKyoTex naar verwachting een dividend van 0 betalen.

De dividendrendement van GenKyoTex is momenteel .

GenKyoTex betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

GenKyoTex betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 verwacht. Dit komt overeen met een dividendrendement van 0 %.

GenKyoTex wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van GenKyoTex van 28-8-2024 ter hoogte van 0 te ontvangen, moest je het aandeel voor de ex-datum op 28-8-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 28-8-2024.

In het jaar 2023 heeft GenKyoTex 0 aan dividenden uitgekeerd.

De dividenden van GenKyoTex worden in uitgekeerd.